G-protein coupled receptors (GPCRs) are among the most diverse and ubiquitous proteins in all of biology. The epidermal growth factorseven span transmembrane (EGF-TM7) subfamily of adhesion GPCRs is a small subset whose members are mainly expressed on the surface of leukocytes. The EGF domains on the N-terminus add significant size to these receptors and they are considered to be among the largest members of the TM7 family. Although not all of their ligands or downstream targets have been identified, there is evidence implicating the EGF-TM7 family diverse processes such as cell adhesion, migration, inflammation, and autoimmune disease. Recent studies have identified expression of EGF-TM7 family members on human neoplasms including those of the thyroid, stomach, colon, and brain. Their presence on these tissues is not surprising given the ubiquity of GPCRs, but because their functional significance and pathways are not completely understood, they are of tremendous clinical and scientific interest. Current evidence suggests that expression of certain EGF-TM7 receptors is correlated with tumor grade, confers a more invasive phenotype, and increases the likelihood of metastatic disease. In this review, we will discuss the structure, function, and regulation of these receptors. We also describe the expression of these receptors in human cancers and explore their potential mechanistic significance.
diverged. 12, 13 Phylogenetic analysis prompted the development of the GRAFS classification system for G-protein coupled receptors, which consists of five families: i) glutamate (G); ii) rhodopsin (R); iii) adhesion (A); iv) frizzled/taste2 (F); and v) secretin (S). 14 The glutamate receptor family possesses a unique Venus fly trap N-terminus domain that allows the receptor to close around its ligand. Members of this family include the metabotropic glutamate receptors, GABA receptors, several putative taste receptors (TAS1), and a single calcium-sensing receptor. The rhodopsin family is the largest amongst G protein coupled receptors (GPCRs) and contains receptors for neuropeptides, chemokines, prostaglandins, biogenic amines, glycoprotein hormones, and olfactory and visual receptors.
The EGF-TM7 receptors belong to the adhesion receptor family. The adhesion GPCRs are divided into eight clusters or groups identified by Roman numerals. 15 All EGF-TM7 receptors are members of Group II except for ETL, which is found in Group I. Under the GRAFS classification system, all adhesion GPCRs feature GPCR-like transmembrane domains with an N-terminus containing an adhesion-like motif such as EGF-like repeats, mucin-like regions, or cysteine-rich motifs, and are believed to play a role in cell adhesion. 4, 14, 16 EMR2 and EMR3 are the only members of the adhesion GPCR family without mouse orthologues, further supporting the hypothesis that the EGF-TM7 subfamily arose from duplication events.
The fourth family of GPCRs contains two clusters and is referred to as the frizzled/taste2 receptor family. This group of taste receptors (TAS2) contains consensus sequences unique to the frizzled receptors and absent in the TAS1 receptors of the glutamate receptor family. 14 Frizzled receptors are notable for mediating Wnt signaling and regulate cell fate and polarity during development. 14, 17, 18 Members of the secretin receptor family are capable of binding large, typically paracrine-acting peptides. They are named after the first discovered member of the family and include the secretin receptor, glucagon receptor, calcitonin receptor, corticotropin-releasing hormone receptor, growth hormone-releasing hormone receptor, and others. 14 Despite the tremendous diversity in the TM7 family, the EGF-TM7 subfamily remains unique for several reasons. First, not much is known of their downstream targets and specific ligand interactions. Furthermore, due to their fairly restricted expression profile, the functional significance of these receptors remains elusive. Finally, and perhaps most interestingly, members of this family have been detected in various malignancies, implicating them in tumor invasion, metastatic spread, and angiogenesis.
Receptor structure
Traditional GPCRs operate through a well-understood molecular cascade. Ligand binding stabilizes the receptor and stimulates a heterotrimeric guanine nucleotide-binding regulatory (G) protein to dissociate into and subunits. These subunits modulate a number of effectors including adenylyl cyclase, phospholipase, phosphodiesterase, and ion channels, which subsequently regulate the concentration of second-messengers that elicit a cellular response. It is important to note that there is evidence suggesting certain TM7 receptors may operate through G-protein-independent mechanisms. For example, in Dictyostelium, a unicellular eukaryote, cyclic adenosine monophosphate receptors (cAMP) are capable of inducing calcium influx, mitogen-activated protein kinase 1 activation, and cAMP receptor 1 phosphorylation by G-protein-independent mechanisms. 19 Other TM7 receptors, such as those of the EGF-TM7 subfamily, may facilitate cell adhesion without activation of their signaling cascades, although this is less likely given the tendency of structurally similar proteins to engage the G subunit. The EGF-TM7 receptors contain distinct regions including a cleavable signal peptide, N-terminal EGF domain region, stalk, class B TM7 region, and cytoplasmic tail (Figure 1 ). Most are expressed as heterodimers consisting of extracellular and TM7/cytoplasmic domains. The extracellular domains of these receptors represent some of the largest in the entire TM7 family and typically contain adjacent EGF-like domains. Like the TM7 family, the EGF domain is among the most ubiquitous in biology. EGF domains are linked to numerous physiologic processes including cell adhesion, neural development, coagulation, and fibrinolysis. 20 Mutations in the EGF domains of biologically important receptors are associated with diverse human diseases. For example, mutations of the low-density lipoprotein receptor, factor IX, and fibrillin cause familial hypercholesterolemia, hemophilia B, and Marfan syndrome, respectively. [21] [22] [23] The EGF-TM7 family is almost universally characterized by the presence of alternative splicing, producing isoforms with variable number and arrangement of EGF domains. 24 Within this family, the EGF domains of EMR2 and CD97 demonstrate the most homology, differing by only six amino acids. 8 Although EGF domains mediate the interactions between these receptors and their ligands in a calcium-dependent fashion, the intricacies of ligand binding are not fully understood. Calcium is believed to provide conformational stability to inter-domain linkages, producing EGF repeats that are highly resistant to proteolysis. 25 Such properties seem ideally suited for cell-cell or cell-extracellular matrix interactions, particularly those involved in adhesion or migration. Additionally, these receptors may interact with other cell surface proteins as recent data has demonstrated heterodimerization of CD97 with lysophosphatidic acid receptor 1 (LPAR1) in prostate cancer cells. 26 Expression of epidermal growth factor epidermal growth factor seven-span transmembrane members EMR2 is expressed on monocytes, macrophages, myeloid dendritic cells, and granulocytes, but not lymphocytes. 8, 27 There are five EMR2 isoforms, four of which are depicted in Figure 1 , that differ in their number of EGF-like domains. Interestingly, EMR2 and EMR3 are the only members of the EGF-TM7 family that lack mouse orthologs. EMR2 expression is highest in mature CD16 + monocytes, macrophages, and blood dendritic cell antigen-3 + myeloid dendritic cells, and lowest in granulocytes. 27 Functional significance of the epidermal growth factor-like module containing mucinlike hormone receptor 2 family in leukocytes
The study of EMR2 is hampered by the lack of mouse orthologues. As the EGF domains of EMR2 demonstrate significant homology, it is not surprising that chondroitin sulfate (CS) has been identified as a ligand. 28 CS is one of two major types of glycosaminoglycans (GAGs), the other being heparin/heparin sulfate, which differ by the composition of their amino sugars. Furthermore, there are three types of CS: i) chondroitin sulfate A (CSA); ii) chondroitin sulfate B (CSB), which includes dermatan sulfate, an isomer with variable glucuronic acid residues; iii) chondroitin sulfate C (CSC). 29 EMR2 has been shown to bind dermatan sulfate on B cells, but does not induce signaling or cell activation. 30 This supports previous findings suggesting a role for EGF-TM7 family receptors in cell adhesion.
Functionally, EMR2 has also been implicated in autoimmune disease and neutrophil function. EMR2-positive macrophages and dendritic cells are increased in the synovium of patients with rheumatoid arthritis (RA). 29 GAG expression in the inflammatory synovium and chondrocytes in RA is predominantly dermatan sulfate, while fibrotic synovium is generally comprised of CSA and CSC. 31 Thus, the interaction of EMR2 with dermatan sulfate provides a plausible mechanism underlying the persistent inflammation in RA and other autoimmune diseases. Additionally, EMR2 has been implicated in neutrophil function by mediating activation and cytokine secretion in the presence of lipopolysaccharide and IL-10. 32 Circulating neutrophils in patients with systemic inflammation also exhibit elevated EMR2 expression. 33 Additionally, foamy macrophages in atherosclerotic vessels and splenocytes in patients with Gaucher's disease have been shown to express EMR2. 34 
Expression of epidermal growth factor-like module containing mucin-like hormone receptor 2 in cancers
Although once thought to be leukocyte-restricted, several studies have identified EMR2 in human neoplasms. EMR2 expression has been characterized in colorectal, breast, and brain cancers, although heterogeneity in expression patterns is detected even within these tumor types. Aust et al. found that among 81 colorectal cancer cell lines, only 8 demonstrated greater than 50% expression of the EMR2 protein, though strong EMR2 expression was observed in a subpopulation of tumor-infiltrating macrophages. 35 Similarly, Davies et al. examined 5 breast cancer cell lines and found that only 2 qualified as high expressers, with EMR2 localization restricted to the peripheral membrane and perinuclear cytoplasm. 36 Recently, our group examined EMR2 expression in primary glioblastoma (GBM) tissue derived from 5 patients as well as 3 established GBM cell lines, showing heterogeneous expression of EMR2 across all specimens. 37 Furthermore, a cDNA microarray analysis of early-stage and advanced bladder tumors found EMR2 to be among the top-ranked genes identified. 38 Unlike CD97, the most well-characterized member of the EGF-TM7 family, EMR2 is not expressed in gastric, pancreatic, and esophageal carcinomas, which may be explained by the multiplicity of EMR2 mRNA isoforms present in single cell lines or types. 39 As such, while EMR2 immunopositivity can be encountered in these neoplasms, not all tumors of any given ontology will express this protein.
Functional significance of epidermal growth factor-like module containing mucin-like hormone receptor 2 in cancers
Among patients with EMR2-positive cancers, the clinicopathologic significance of this protein varies by tumor type. In colorectal cancer, EMR2 did not significantly affect clinical parameters such as tumor stage or systemic invasion. 35 However in breast cancer, EMR2 appears to have a functional role in disease aggressiveness. EMR2 is highly expressed in invasive carcinomas and a subset of ductal carcinoma in situ (DCIS), but not in normal breast epithelium. 36 When comparing in situ and invasive carcinomas, EMR2 expression was significantly higher in the invasive group, suggesting that EMR2 may contribute to this invasive phenotype. 36 Interestingly, among these invasive carcinomas, increased cytoplasmic expression of EMR2 was found to correlate with a higher tumor grade, while increased nuclear expression of EMR2 correlated with prolonged relapse-free survival and overall survival. 36 In DCIS, EMR2 expression did not show any correlation with important clinical and pathologic parameters such as patient age, tumor grade, estrogen receptor positivity, tumor progression, or overall survival. 36 Our group recently characterized the functional significance of EMR2 and its fellow EGF-TM7 member EMR3 in human GBM. 37, 40 EMR2 was found to confer an invasive phenotype in vitro, with no effect on tumor proliferation. More importantly, when stratifying tumors by their relative expression of EMR2, there is an inverse relationship between EMR2 gene expression and overall survival; patients whose tumors express high levels of EMR2 were found to have significantly shorter overall survival compared to those with tumors expressing low levels of EMR2, suggesting that EMR2 expression may represent a clinically relevant biomarker in this disease. 37, 40 We believe that the survival discrepancy among patients with high versus low EMR2 expressing tumors is likely related to the invasive potential of their tumors. The mechanisms underlying EMR2 expression in GBM are not well understood, nor are the possible downstream targets of the receptor, however the upregulation of EGF-TM7 family members in GBM may represent a unique genetic subtype characterized by a highly invasive phenotype, a step in tumor oncogenesis that provides a selective advantage due to its invasive potential.
Functional data suggest that EMR2 may serve as a biomarker of increased malignancy or invasive potential in breast cancer and GBM, although perhaps not in colorectal, gastric, pancreatic, and esophageal cancers (Table 1) . EMR2 is also a useful cell surface marker for tumorinfiltrating macrophages and neutrophils. Taken together, EMR2 is a critically important member of the EGF-TM7 family that may one day help stratify patients by tumor phenotype, allow for more accurate prognoses, and serve as a target for novel therapeutic agents. CD97, which shares significant homology with EMR2, has been the target of therapeutic intervention through neutralizing antibodies and a proposed vaccine against its ligand CD55; perhaps a similar approach can be used for EMR2. 41, 42 Such inhibition of EMR2 may represent one strategy for limiting local and systemic invasion of neoplastic cells. Given that EMR2 expression has been tied to patient survival, such therapies could conceivably improve clinical outcomes for patients with EMR2-positive tumors.
Conclusions
The association of the EGF-TM7 family member EMR2 with multiple human cancers poses interesting questions with respect to how and why neoplastic cells would upregulate their expression of leukocyte receptors. Leaning on data demonstrating the role of these proteins in adhesion, migration, invasion, and angiogenesis, it is reasonable to postulate that EMR2-positive neoplasms possess a greater capacity for infiltrative and metastatic spread. Accordingly, therapies targeting EMR2 may be useful in attenuating both local and systemic invasion, though it remains to be seen whether a clinically relevant response is achievable. One may also hypothesize that EMR2 facilitates immune evasion in cancer cells, as the presence of EGF-TM7 family members on the surface of normal leukocytes may compromise the host's ability to mount an effective immune response against EMR2-expressing cancer cells. Moving forward, recognized challenges in the study of adhesionGPCRs include their complex chimeric protein structure, limited knowledge of downstream intracellular targets, and paucity of reagents. 43 Nonetheless, ongoing advances in structural and molecular biology, genome-wide analyses such as the Cancer Genome Atlas, and accumulating data on the role of the EGF-TM7 family in neoplastic states will shed new insight into these markers and aid in the development of targeted therapies for patients with aggressive and often highly invasive cancers. 
